Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer (Q37807360)

23 August 2017

Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer (English)

1 reference

23 August 2017

1 reference

2

1 reference

23 August 2017

Jiezhong Chen

1

0 references

author name string

Andrew Katsifis

series ordinal

3

1 reference

23 August 2017

1 December 2010

1 reference

Journal of Cellular Biochemistry

23 August 2017

1 reference

23 August 2017

111

1 reference

23 August 2017

5

1 reference

23 August 2017

1082-1086

1 reference

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

23 August 2017

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

The EGFR as a target for anticancer therapy--focus on cetuximab

21 January 2018

1 reference

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

Role of Src family kinases in acquired resistance to EGFR therapies in cancer.

21 January 2018

1 reference

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

21 January 2018

1 reference

Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT?

21 January 2018

1 reference

The signal pathways in azoxymethane-induced colon cancer and preventive implications

21 January 2018

1 reference

Multiple signal pathways in the leukemogenesis and therapeutic implications.

21 January 2018

1 reference

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition

21 January 2018

1 reference

Up-regulation of GPR48 induced by down-regulation of p27Kip1 enhances carcinoma cell invasiveness and metastasis

21 January 2018

1 reference

Obesity, the PI3K/Akt signal pathway and colon cancer

21 January 2018

1 reference

Activating SRC mutation in a subset of advanced human colon cancers

21 January 2018

1 reference

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer

21 January 2018

1 reference

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

Epidermal growth factor receptor: mechanisms of activation and signalling.

21 January 2018

1 reference

Lessons from hereditary colorectal cancer

21 January 2018

1 reference

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

Nuclear EGFR contributes to acquired resistance to cetuximab

21 January 2018

1 reference

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

Systemic therapy for colorectal cancer

21 January 2018

1 reference

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

PTEN status in advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

21 January 2018

1 reference

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

21 January 2018

1 reference

KRAS mutation testing in colorectal cancer

21 January 2018

1 reference

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.

21 January 2018

1 reference

Next-generation DNA sequencing

21 January 2018

1 reference

EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor

21 January 2018

1 reference

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

21 January 2018

1 reference

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.

21 January 2018

1 reference

A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.

21 January 2018

1 reference

Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.

21 January 2018

1 reference

Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer

21 January 2018

1 reference

Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines

21 January 2018

1 reference

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCB.22905

1 reference

23 August 2017

1 reference

PubMed ID

21053280